COMPANY PROFILE

Aldagen

Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure

Durham, United StatesFounded 2001Biotech & Life Sciences

Valuation $100–250M Last recorded · 2008

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Aldagen

Aldagen, a subsidiary of Cytomedix, Inc., specializes in developing regenerative cell therapies targeting vascular conditions. The company utilizes proprietary technology to isolate a specific population of stem cells from a patient's bone marrow, which constitutes less than 1% of all bone marrow cells. These isolated cells have shown potential in preclinical studies and clinical trials to promote the regeneration of various cell types and tissues, including the formation of new blood vessels, known as angiogenesis. Aldagen's product pipeline includes ALD-301 for critical limb ischemia, ALD-201 for ischemic heart failure, and ALD-401 for ischemic stroke. The company operates in the regenerative medicine market, serving patients with severe vascular conditions. Its business model focuses on developing and commercializing these cell-based therapies, generating revenue through product sales and potential partnerships.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2001
Headquarters: Durham, United States
Employees: 4
Open positions: None listed
Dealroom signal: 55.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Feb 2012	$0	—	Nuo Therapeutics	↗
DEBTDebt	Jan 2012	$585K	—	Undisclosed	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Aldagen website traffic

Latest recorded traffic for Aldagen is 240 monthly website visits. Aldagen's team grew 0% over the past year.

Latest monthly visits240 1-year team growth0%

Monthly website visitsMay 2017–Aug 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
SOSoProsFocus on the potential of microalgae, especially the useful ingredients of labyrinthula auranthiochytrium, in the healthcare business	Tsukuba, Japan	Operational
IKIkarovecBi-functional gene therapies for chronic eye diseases	Norwich, United Kingdom	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
APApoGlyxDeveloping new therapeutic concepts for metabolic and inflammatory diseases with innovative and proprietary Aquaporin technology	Lund Municipality, Sweden	Operational
QTQuell TherapeuticsEngineered T-regulatory cell therapies for immune-driven diseases	London, United Kingdom	Operational